244 related articles for article (PubMed ID: 36602428)
1. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression.
Xia P; Zhang H; Lu H; Xu K; Jiang X; Jiang Y; Gongye X; Chen Z; Liu J; Chen X; Ma W; Zhang Z; Yuan Y
Cancer Commun (Lond); 2023 Mar; 43(3):338-364. PubMed ID: 36602428
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
3. NOP2-mediated m5C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression.
Zhang H; Zhai X; Liu Y; Xia Z; Xia T; Du G; Zhou H; Franziska Strohmer D; Bazhin AV; Li Z; Wang X; Jin B; Guo D
Research (Wash D C); 2023; 6():0184. PubMed ID: 37398932
[TBL] [Abstract][Full Text] [Related]
4. The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression.
Wang Q; Huang Y; Zhu Y; Zhang W; Wang B; Du X; Dai Q; Zhang F; Fang Z
Cancer Med; 2024 Apr; 13(7):e7165. PubMed ID: 38613157
[TBL] [Abstract][Full Text] [Related]
5. MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation.
Wu Y; Wang Y; Yao H; Li H; Meng F; Li Q; Lin X; Liu L
J Exp Clin Cancer Res; 2022 Dec; 41(1):337. PubMed ID: 36476366
[TBL] [Abstract][Full Text] [Related]
6. The m6A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma.
Zeng Z; Wang J; Xu F; Hu P; Hu Y; Zhuo W; Chen D; Han S; Wang F; Zhao Y; Huang Y; Zhao G
Int J Biol Sci; 2024; 20(5):1744-1762. PubMed ID: 38481809
[TBL] [Abstract][Full Text] [Related]
7. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
8. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
9. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma.
Meng J; Ai X; Lei Y; Zhong W; Qian B; Qiao K; Wang X; Zhou B; Wang H; Huai L; Zhang X; Han J; Xue Y; Liang Y; Zhou H; Chen S; Sun T; Yang C
Theranostics; 2019; 9(2):573-587. PubMed ID: 30809294
[No Abstract] [Full Text] [Related]
10. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
12. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.
Peng Q; Hao L; Guo Y; Zhang Z; Ji J; Xue Y; Liu Y; Li C; Lu J; Shi X
J Nat Med; 2023 Jan; 77(1):28-40. PubMed ID: 36068393
[TBL] [Abstract][Full Text] [Related]
14. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
Wang L; Peng JL
Sci Rep; 2023 Jul; 13(1):10755. PubMed ID: 37400463
[TBL] [Abstract][Full Text] [Related]
15. ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM.
Zhou Y; Lin F; Wan T; Chen A; Wang H; Jiang B; Zhao W; Liao S; Wang S; Li G; Xu Z; Wang J; Zhang J; Ma H; Lin D; Li Q
Theranostics; 2021; 11(12):5926-5938. PubMed ID: 33897890
[TBL] [Abstract][Full Text] [Related]
16. Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine.
Guo Y; Li X; Sun X; Wang J; Yang X; Zhou X; Liu X; Liu W; Yuan J; Yao L; Li X; Shen L
Int J Biol Sci; 2019; 15(9):1771-1786. PubMed ID: 31523182
[TBL] [Abstract][Full Text] [Related]
17. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-dependent expression of MAP17 coordinates the Warburg effect to tumor growth in hepatocellular carcinoma.
Dong F; Li R; Wang J; Zhang Y; Yao J; Jiang SH; Hu X; Feng M; Bao Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):121. PubMed ID: 33832535
[TBL] [Abstract][Full Text] [Related]
19. Integrated analyses identify miR-34c-3p/MAGI3 axis for the Warburg metabolism in hepatocellular carcinoma.
Weng Q; Chen M; Yang W; Li J; Fan K; Xu M; Weng W; Lv X; Fang S; Zheng L; Song J; Zhao Z; Fan X; Ji J
FASEB J; 2020 Apr; 34(4):5420-5434. PubMed ID: 32080912
[TBL] [Abstract][Full Text] [Related]
20. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
